Christopher C. Dvorak, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Christopher C. Dvorak, MD

Associate Professor of Clinical Pediatrics, Division of Pediatric Blood and Marrow Transplantation, UCSF Benioff Children’s Hospital

dvorakc@peds.ucsf.edu

Phone: (415) 476-0554 (voice)
Box 1278, UCSF
San Francisco, CA 94143-1278

UCSF Profiles

Cancer Center Membership

Program Member » Hematopoietic Malignancies» Pediatric Malignancies

Research Summary

My primary research focus is the supportive care aspects of pediatric HCT, with a goal of decreasing treatment-related morbidity and mortality, especially infections. I am the Chair of the international Pediatric Blood and Marrow Transplant Consortium’s (PBMTC) Supportive Care Strategy Group, where I lead individuals in the design of pilot multi-center trials in this field. These trials serve as the basis for the design of larger phase III trials in the COG.

In the COG, I serve on the Stem Cell Transplant and (as Vice-Chair) on the Cancer Control & Supportive Care Steering Committees, helping to oversee the design of trials in this field. Furthermore, I am the principal investigator on the Children’s Oncology Group (COG) protocol ACCL1131: An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic HCT. I am also the vice-chair for COG ACCL1034: Impact of Cleaning with Chlorhexidine Gluconate on Reducing Central Line Associate Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms.

I also serve as a member of the protocol design committee for two other Supportive Care trials, including ACCL0934: A Randomized Controlled Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation and ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML). Finally, I am the principal investigator on another COG trial, ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation for Children with JMML.

Education

University of California at San Diego, BS, 1994, Molecular Biology
Vanderbilt University School of Medicine, MD, 1998, Medicine
Stanford University School of Medicine, Intern, 1999, Pediatrics
Stanford University School of Medicine, Resident, 2001, Pediatrics
Stanford University School of Medicine, Fellow, 2005, Hematology/Oncology


Professional Experience

  • 2001-2002
    Staff Physician, Pediatric and Neonatal Intensive Care Units, Stanford University
  • 2002-2004
    Staff Physician, Neonatal Intensive Care Unit, Santa Clara Valley Medical Center
  • 2005-2007
    Clinical Instructor, Division of Pediatric Stem Cell Transplantation, Stanford University
  • 2007-present
    Assistant Professor of Clinical Pediatrics, Division of Pediatric Blood and Marrow Transplantation, UCSF Benioff Children’s Hospital
  • 2013-present
    Associate Professor of Clinical Pediatrics, Division of Pediatric Blood and Marrow Transplantation, UCSF Benioff Children’s Hospital

Honors & Awards

  • 1990-1994
    Regents Scholar, University of California at San Diego
  • 2002-2005
    Arline & Pete Harman Pediatric Fellow, Lucile Packard Foundation for Children's Health
  • 2011
    Pediatric Faculty Leadership Award, UCSF Fellow's College

Selected Publications

  1. Dorsey MJ, Dvorak CC, Cowan MJ, Puck JM. Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. J Allergy Clin Immunol. 2017 Mar; 139(3):733-742.
    View on PubMed
  2. Maziarz RT, Brazauskas R, Chen M, McLeod AA, Martino R, Wingard JR, Aljurf M, Battiwalla M, Dvorak CC, Geroge B, Guinan EC, Hale GA, Lazarus HM, Lee JW, Liesveld JL, Ramanathan M, Reddy V, Savani BN, Smith FO, Strasfeld L, Taplitz RA, Ustun C, Boeckh MJ, Gea-Banacloche J, Lindemans CA, Auletta JJ, Riches ML. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. Bone Marrow Transplant. 2016 Dec 19.
    View on PubMed
  3. Dvorak CC. Musical chairs: in utero HCT via mobilization. Blood. 2016 Nov 17; 128(20):2378-2380.
    View on PubMed
  4. Nademi Z, Slatter MA, Dvorak CC, Neven B, Fischer A, Suarez F, Booth C, Rao K, Laberko A, Rodina J, Bertrand Y, Koltan S, Debski R, Flood T, Abinun M, Gennery AR, Hambleton S, Ehl S, Cant AJ. Hematopoietic Stem Cell Transplant in Patients with Activated PI3K Delta Syndrome. J Allergy Clin Immunol. 2016 Nov 12.
    View on PubMed
  5. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536.
    View on PubMed
  6. de la Morena MT, Leonard D, Torgerson TR, Cabral-Marques O, Slatter M, Aghamohammadi A, Chandra S, Murguia-Favela L, Bonilla FA, Kanariou M, Damrongwatanasuk R, Kuo CY, Dvorak CC, Meyts I, Chen K, Kobrynski L, Kapoor N, Richter D, DiGiovanni D, Dhalla F, Farmaki E, Speckmann C, Español T, Shcherbina A, Hanson IC, Litzman J, Routes JM, Wong M, Fuleihan R, Seneviratne SL, Small TN, Janda A, Bezrodnik L, Seger R, Raccio AG, Edgar JD, Chou J, Abbott JK, van Montfrans J, González-Granado LI, Bunin N, Kutukculer N, Gray P, Seminario G, Pasic S, Aquino V, Wysocki C, Abolhassani H, Dorsey M, Cunningham-Rundles C, Knutsen AP, Sleasman J, Costa Carvalho BT, Condino-Neto A, Grunebaum E, Chapel H, Ochs HD, Filipovich A, Cowan M, Gennery A, Cant A, Notarangelo LD, Roifman CM. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. J Allergy Clin Immunol. 2016 Sep 30.
    View on PubMed
  7. Geerlinks AV, Issekutz T, Wahlstrom JT, Sullivan KE, Cowan MJ, Dvorak CC, Fernandez CV. Severe, persistent, and fatal T-cell immunodeficiency following therapy for infantile leukemia. Pediatr Blood Cancer. 2016 Jun 29.
    View on PubMed
  8. Wahlstrom J, Patel K, Eckhert E, Kong D, Horn B, Cowan MJ, Dvorak CC. Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency. J Allergy Clin Immunol. 2016 Jun 16.
    View on PubMed
  9. Horn B, O'Kane S, Wattier RL, Wahlstrom JT, Melton A, Cowan MJ, Dvorak CC. Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab. Bone Marrow Transplant. 2016 Jun 6.
    View on PubMed
  10. Bailey-Olson M, Cowan M, Dvorak C, Mueller S, Owens A, Wahlstrom J, Horn B. Evaluation of Pre-Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies. J Pediatr Oncol Nurs. 2016 Feb 22.
    View on PubMed
  11. Levy ER, Musick L, Zinter MS, Lang T, Cowan MJ, Weintrub PS, Dvorak CC. Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population. Pediatr Infect Dis J. 2016 Feb; 35(2):135-41.
    View on PubMed
  12. Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, Walsh TJ, Szabolcs P, Boeckh MJ, Auletta JJ, Lindemans CA, Zanis-Neto J, Malvezzi M, Lister J, de Toledo Codina JS, Sackey K, Chakrabarty JL, Ljungman P, Wingard JR, Seftel MD, Seo S, Hale GA, Wirk B, Smith MS, Savani BN, Lazarus HM, Marks DI, Ustun C, Abdel-Azim H, Dvorak CC, Szer J, Storek J, Yong A, Riches MR. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016 Apr; 51(4):573-80.
    View on PubMed
  13. Zinter MS, Spicer A, Orwoll BO, Alkhouli M, Dvorak CC, Calfee CS, Matthay MA, Sapru A. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol. 2016 Feb 1; 310(3):L224-31.
    View on PubMed
  14. Alexander S, Pole JD, Gibson P, Lee M, Hesser T, Chi SN, Dvorak CC, Fisher B, Hasle H, Kanerva J, Möricke A, Phillips B, Raetz E, Rodriguez-Galindo C, Samarasinghe S, Schmiegelow K, Tissing W, Lehrnbecher T, Sung L. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec; 16(16):e604-10.
    View on PubMed
  15. Zinter MS, Dvorak CC, Spicer A, Cowan MJ, Sapru A. New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients. Crit Care Med. 2015 Sep; 43(9):1986-94.
    View on PubMed
  16. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GM, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2154-9.
    View on PubMed
  17. Bode SF, Ammann S, Al-Herz W, Bataneant M, Dvorak CC, Gehring S, Gennery A, Gilmour KC, Gonzalez-Granado LI, Groß-Wieltsch U, Ifversen M, Lingman-Framme J, Matthes-Martin S, Mesters R, Meyts I, van Montfrans JM, Pachlopnik Schmid J, Pai SY, Soler-Palacin P, Schuermann U, Schuster V, Seidel MG, Speckmann C, Stepensky P, Sykora KW, Tesi B, Vraetz T, Waruiru C, Bryceson YT, Moshous D, Lehmberg K, Jordan MB, Ehl S. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015 Jul; 100(7):978-88.
    View on PubMed
  18. Mehta PA, Zhang MJ, Eapen M, He W, Seber A, Gibson B, Camitta BM, Kitko CL, Dvorak CC, Nemecek ER, Frangoul HA, Abdel-Azim H, Kasow KA, Lehmann L, Gonzalez Vicent M, Diaz Pérez MA, Ayas M, Qayed M, Carpenter PA, Jodele S, Lund TC, Leung WH, Davies SM. Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1273-7.
    View on PubMed
  19. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015 Apr; 37(2):236-45.
    View on PubMed
  20. Holter-Chakrabarty JL, Pierson N, Zhang MJ, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, Epstein RB, Lazarus HM, Olsson RF, Selby GB, Williams KM, Cooke KR, Pasquini MC, McCarthy PL. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1251-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI